Welcome to our dedicated page for Kyowa Hakko news (Ticker: KYKOY), a resource for investors and traders seeking the latest updates and insights on Kyowa Hakko stock.
News for KYOWA HAKKO KOGY UNSP/ADR (KYKOY) centers on announcements from Kyowa Kirin Co., Ltd., a Japan-based global specialty pharmaceutical company. Recent releases highlight clinical trial milestones, scientific presentations, strategic collaborations and portfolio decisions across the company’s focus areas in immunology, hematology-oncology, bone and mineral disorders, and rare diseases.
A major theme in Kyowa Kirin’s news flow is the development of rocatinlimab, an investigational anti-OX40 human monoclonal antibody described as a potential T-cell rebalancing therapy for moderate to severe atopic dermatitis. Updates include top-line results from Phase 3 ROCKET trials such as HORIZON, IGNITE and the long-term ASCEND extension, as well as planned presentations at major dermatology congresses. These articles detail efficacy endpoints like EASI-75 and Investigator Global Assessment scores, safety findings and long-term maintenance data.
Another recurring topic is Kyowa Kirin’s work in hematology and hemato-oncology. News includes a global strategic collaboration with Kura Oncology to develop and commercialize ziftomenib, a selective oral menin inhibitor in development for acute myeloid leukemia and other hematologic malignancies. Releases describe how responsibilities are shared between the companies in the United States and other regions.
Kyowa Kirin also reports extensively on X-linked hypophosphatemia (XLH), sharing real-world evidence from the XLH Disease Monitoring Program and new analyses of disease burden, work productivity and treatment outcomes. Additional items cover presentations on burosumab (CRYSVITA) and XLH at scientific meetings, as well as updates on a long-standing research alliance with La Jolla Institute for Immunology and the decision to end distribution of Fareston (toremifene) tablets in the United States.
Investors and observers can use this news stream to follow Kyowa Kirin’s disclosed clinical progress, research partnerships and portfolio focus as they relate to the KYKOY ADR.
Kyowa Kirin announces successful Phase 2 study results for KHK4083, an anti-OX40 monoclonal antibody for treating moderate to severe atopic dermatitis. The trial met primary endpoints, showing significant improvement in the Eczema Area and Severity Index (EASI) at 16 weeks compared to placebo. Conducted in multiple countries with 274 patients, the study demonstrated ongoing efficacy beyond the initial 16 weeks. Common adverse events were reported, but no fatalities occurred. The company looks forward to sharing comprehensive results in future publications and presentations.
Kyowa Kirin and MEI Pharma announced that the first patient has been dosed in a pivotal Phase 2 study of zandelisib in Japan. This multicenter, open-label trial aims to evaluate zandelisib as a monotherapy for patients with relapsed or refractory indolent B-cell non-Hodgkin's lymphoma (iNHL). In partnership, both companies seek to expand zandelisib's global development, with Kyowa Kirin holding exclusive rights outside the U.S. The study will include 60 patients, primarily measuring the objective response rate, and is expected to conclude by September 2024.